Advertisement
BMY or REGN or ZTS
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Regeneron Pharmaceuticals (REGN) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- BMY leads YTD performance at +12.04%, supported by its growth portfolio and positive clinical data, trading at a P/E of 17.26 with a $122B market cap.
- REGN shows strong 1-year returns of +18.20% driven by Dupixent expansions, but YTD at +2.81% amid Eylea challenges; P/E 18.05, market cap $79B.
- ZTS faces headwinds with a 1-year decline despite +7.15% YTD, due to Librela concerns; lowest market cap at $51B, P/E 19.36.
- All three exhibit relative value with P/E ratios under 20, but BMY offers the most attractive valuation and momentum in recent market activity.
- Recent approvals and pipeline catalysts bolster sentiment for BMY and REGN, while ZTS contends with safety issues and guidance cuts.
- Healthcare sector exposure varies: human pharma for BMY and REGN, animal health for ZTS.
Introduction
This stock comparison evaluates BMY (Bristol-Myers Squibb), REGN (Regeneron Pharmaceuticals), and ZTS (Zoetis) amid evolving healthcare dynamics. These companies operate in biopharma and animal health, sectors influenced by regulatory approvals, pipeline progress, and market sentiment shifts in recent weeks. Traders seeking momentum plays may eye relative performance, while long-term investors could assess valuation and growth drivers like oncology innovations and immunotherapy expansions. This analysis highlights contrasts in recent price behavior, business models, and positioning to aid informed relative performance decisions in the current environment.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a global biopharmaceutical leader focused on oncology, hematology, immunology, cardiovascular, and neuroscience therapies. Its portfolio includes blockbusters like Opdivo (PD-1 inhibitor), Eliquis (anticoagulant), and emerging assets such as Camzyos for hypertrophic cardiomyopathy (HCM) and Cobenfy for schizophrenia. In recent market activity, BMY shares have shown resilience, posting YTD gains of 12.04% and trading around $59.73 with a market cap of $122B. Positive momentum stems from FDA approvals, strong clinical data—like Camzyos updates—and growth portfolio expansion offsetting legacy declines. Sentiment has improved on pipeline catalysts and attractive valuation (P/E 17.26), with analysts raising targets amid robust Q4 results and 2026 revenue guidance of $46B–$47.5B.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN) specializes in biotechnology, developing treatments for eye diseases, allergies, inflammation, cancer, and rare conditions via proprietary platforms in antibodies, bispecifics, and gene therapies. Key products include Eylea (VEGF inhibitor for ophthalmology), Dupixent (for atopic dermatitis and asthma), and Libtayo (immunotherapy). Recent weeks have seen mixed price action for REGN, with YTD +2.81%, 1-year +18.20%, and shares near $749 (market cap $79B). Gains reflect Dupixent approvals, like for bullous pemphigoid in Japan, and pipeline momentum, though Eylea biosimilar pressures temper enthusiasm. Trading at P/E 18.05, sentiment balances robust Q4 revenues ($3.9B) against competition, with analysts optimistic on 2026 double-digit growth.
ZTS Overview and Recent Performance
Zoetis (ZTS), the world's leading animal health company, provides medicines, vaccines, diagnostics, and precision solutions for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry). Flagship products target dermatology, parasiticide, and osteoarthritis like Librela. In recent market activity, ZTS shares have underperformed, down sharply over the past year despite YTD +7.15%, trading around $116 (market cap $51B). Headwinds include Librela safety concerns, reduced vet visits, and guidance cuts, leading to steeper declines than peers. At P/E 19.36, sentiment reflects challenges in U.S. companion animal demand, offset by international livestock growth and a 6% dividend hike; analysts see long-term potential in pipeline and emerging markets.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 350 total bots that trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current conditions—based on factors like volatility (low, medium, high), strategies (technical, fundamental), and timeframes (5min expert to 60min intermediate)—earn a spot among the 25+ trending ones. These bots deliver impressive stats, with top performers posting 30-day annualized returns up to 171%, win rates of 88-100%, and low drawdowns in sectors like tech and aerospace. Diverse styles include price action signals, risk-managed virtual agents, and brokerage signals, enabling copy trading without minimums. Explore these high performers to enhance your strategy in today's market.
Head-to-Head Comparison
BMY, REGN, and ZTS contrast in business models: BMY and REGN emphasize human therapeutics (oncology/immunology vs. biotech platforms), while ZTS dominates animal health with diagnostics/vaccines. Growth drivers differ—BMY's diversified portfolio offsets patent cliffs; REGN leverages Dupixent expansions; ZTS eyes international/emerging but faces U.S. softness. Recent momentum favors BMY (top YTD), with ZTS lagging on safety risks. Risk factors include regulatory hurdles for all, biosimilars for REGN, and consumer trends for ZTS. Valuation sensitivity shows BMY cheapest (P/E 17), amid stable healthcare exposure; sentiment tilts to human pharma stability over animal cyclicality.
Tickeron AI Verdict
Tickeron's AI currently favors BMY based on superior trend consistency, YTD outperformance, pipeline catalysts like Camzyos data, and relative valuation edge. Its growth portfolio stability and lower P/E position it probabilistically stronger amid recent healthcare rotations, though REGN's Dupixent upside merits monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileREGN’s FA Score has 2 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 2 green, 3 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 2 bullish TA indicator(s), and ZTS’s TA Score reflects 5 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 6 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
- ZTS’s TA Score: 5 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +1.84% price change this week, while REGN (@Biotechnology) price change was +0.40% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +2.64% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.86%. For the same industry, the average monthly price growth was +3.78%, and the average quarterly price growth was +6.95%.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.54%. For the same industry, the average monthly price growth was +11.06%, and the average quarterly price growth was +10.78%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.60%. For the same industry, the average monthly price growth was +7.76%, and the average quarterly price growth was +1.16%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+3.54% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (+1.60% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| BMY | REGN | ZTS | |
| Capitalization | 121B | 79.2B | 51.6B |
| EBITDA | 15.2B | 5.82B | 4.07B |
| Gain YTD | 12.061 | -2.793 | -1.621 |
| P/E Ratio | 17.09 | 18.07 | 20.39 |
| Revenue | 48.2B | 14.3B | 9.47B |
| Total Cash | N/A | 8.61B | N/A |
| Total Debt | 47.1B | 2.71B | 9.24B |
BMY | REGN | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 60 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 3 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 82 | 75 | 100 | |
SMR RATING 1..100 | 23 | 54 | 16 | |
PRICE GROWTH RATING 1..100 | 21 | 26 | 60 | |
P/E GROWTH RATING 1..100 | 70 | 41 | 85 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for BMY (39) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ZTS’s and somewhat faster than BMY’s over the last 12 months.
REGN's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as BMY (82) in the Pharmaceuticals Major industry, and is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to BMY’s and similarly to ZTS’s over the last 12 months.
ZTS's SMR Rating (16) in the Pharmaceuticals Generic industry is in the same range as BMY (23) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for REGN (54) in the Biotechnology industry. This means that ZTS's stock grew similarly to BMY’s and somewhat faster than REGN’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as REGN (26) in the Biotechnology industry, and is somewhat better than the same rating for ZTS (60) in the Pharmaceuticals Generic industry. This means that BMY's stock grew similarly to REGN’s and somewhat faster than ZTS’s over the last 12 months.
REGN's P/E Growth Rating (41) in the Biotechnology industry is in the same range as BMY (70) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that REGN's stock grew similarly to BMY’s and somewhat faster than ZTS’s over the last 12 months.
| BMY | REGN | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 48% | N/A | 6 days ago 52% |
| Stochastic ODDS (%) | 1 day ago 50% | 1 day ago 69% | 1 day ago 63% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 51% | 1 day ago 57% |
| MACD ODDS (%) | 1 day ago 47% | 1 day ago 51% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 52% | 1 day ago 66% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 54% | 1 day ago 65% | 1 day ago 54% |
| Advances ODDS (%) | 5 days ago 54% | 21 days ago 64% | 1 day ago 51% |
| Declines ODDS (%) | 9 days ago 53% | 6 days ago 51% | 6 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 51% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 71% | 1 day ago 60% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BNO | 47.45 | 1.98 | +4.35% |
| United States Brent Oil | |||
| CWVX | 42.78 | 0.60 | +1.42% |
| Tradr 2X Long CRWV Daily ETF | |||
| RDVY | 74.52 | 0.02 | +0.03% |
| First Trust Rising Dividend Achiev ETF | |||
| YLDE | 55.84 | -0.01 | -0.02% |
| Franklin ClearBridge Enhanced Inc ETF | |||
| QTAP | 49.15 | -0.04 | -0.08% |
| Innovator Growth-100 Acltd Ps ETF™ April | |||